Table 2.
Patient demographics and baseline characteristics (safety population)
| Previous Active | Previous Placebo | Prior DBS Patients | All | |
| Groupa (n = 61) | Groupa (n = 79) | Group (n = 61) | (N = 223b) | |
| Age (years), mean (SD) | 64.2 (9.93) | 65.8 (8.80) | 60.2 (9.20) | 63.7 (9.31) |
| Age (years), <65, n (%) | 28 (45.9) | 31 (39.2) | 39 (63.9) | 109 (48.9) |
| Age (years), ≥65, n (%) | 33 (54.1) | 48 (60.8) | 22 (36.1) | 114 (51.1) |
| Sex, Male, n (%) | 34 (55.7) | 45 (57.0) | 41 (67.2) | 131 (58.7) |
| Race, White, n (%) | 58 (95.1) | 74 (93.7) | 54 (88.5) | 208 (93.3) |
| BMI (kg/m2), mean (SD) | 25.8 (6.0) | 25.7 (4.8) | 27.3 (4.9) | 26.1 (5.2) |
| Years since PD diagnosis, mean (SD) | 11.2 (4.5) | 10.0 (4.1) | 14.7 (6.3) | 11.8 (5.3) |
| Duration of levodopa treatment (years), mean (SD) | 8.7 (3.7) | 7.8 (4.0) | 11.9 (5.4) | 9.3 (4.7) |
| Duration of levodopa-induced dyskinesia (years), mean (SD) | 4.6 (3.4) | 4.0 (2.5) | 8.0 (4.4) | 5.3 (3.7) |
BMI, body mass index; DBS, deep-brain stimulation; PD, Parkinson’s disease. aThese patients were previously enrolled in either EASE LID or EASE LID 3. bStudy includes 22 patients who enrolled after a time gap following participation in double-blind studies (EASED, EASE LID, EASE LID 3) and were not summarized as a subgroup in subsequent analyses due to small sample size.